A Phase 3 interventional study of Bexagliflozin and Placebo in Type 2 Diabetes Mellitus, sponsored by Theracos. Completed at 157 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-07-14.
Sponsored by Theracos · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Bexagliflozin · Diabetes Mellitus, Type 2.
Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 2 that started in 2015, is one of 5 in phase 3, and was the 3rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Baylor Research Institute · Sites in United States
Ages 18–84
By country, each count listing its studies:
Bexagliflozin: first FDA approval 2023 (BRENZAVVY). What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,700 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 64 across the 15 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 3 most frequent:
Theracos is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.
17 studies in Diabetes Mellitus, Type 2 by Theracos: none open now, none under way, none of them phase 3. Of 16 finished, 16 (100%) have results posted.
Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, this one has the largest enrollment, is one of 2 that started in 2015, is one of 6 in phase 3, and was the 5th registered.
Theracos’s Diabetes Mellitus, Type 2 studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Theracos’s 17 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.
The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.
Approximately 130 investigative sites globally are planned to participate in this study.
An estimated 1650 subjects with inadequately controlled T2DM and an elevated risk of cardiovascular adverse events will be randomized to bexagliflozin tablets, 20 mg, or placebo in a ratio of 2:1 in addition to the background anti-diabetic medications.
The study is an event-driven trial. The treatment period will end when the last randomized subject has completed at least 52 weeks of treatment and a total of at least 134 subjects have experienced a cardiac event.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1: A history of atherosclerotic vascular disease Group 2: A history of heart failure Group 3: Age ≥ 55 years with diabetes for ≥ 10 years, uncontrolled hypertension, currently smoking, reduced kidney function, or cholesterol problems
Exclusion Criteria:
Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
Drug: Bexagliflozin
Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
Drug: Placebo
20 mg, tablet
Also known as: EGT0001442, EGT0001474
20 mg tablet to match active comparator
Change in HbA1c From Baseline to Week 24
The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.
Time frame: 24 weeks
Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin
To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes
Time frame: 24 weeks
Change in Body Weight From Baseline to Week 48
To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo
Time frame: 48 weeks
Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline
To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo
Time frame: 24 weeks
Change in HbA1c From Baseline Over Time
To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks
Time frame: Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168
Change in Fasting Plasma Glucose Over Time
To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks
Time frame: Baseline (week 0) and weeks 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168
Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification
To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period
Time frame: 24 week
Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification
To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period
Time frame: Duration of study (168 weeks)
Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent
To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period
Time frame: 24 weeks
Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent
To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study
Time frame: Duration of study (168 weeks)
Proportion of Participants With Incidence of Hospitalization for Heart Failure
To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline
Time frame: Duration of study (168 weeks)
A total of 1700 patients were recruited from 10 countries: Canada, Czech Republic, Demark, Republic of Korea, Mexico, the Netherlands, Poland, Russian Federation, Taiwan, and the United States.
| Milestone | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Started | 1133 | 567 |
| Completed | 1089 | 542 |
| Not completed | 44 | 25 |
| Withdrew: Adverse event | 9 | 3 |
| Withdrew: Death | 7 | 7 |
| Withdrew: Lost to follow-up | 8 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 17 | 13 |
| Withdrew: The subject was randomized, but did not take any investigational product | 1 | 0 |
| Milestone | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Started | 1133 | 567 |
| Completed | 987 | 482 |
| Not completed | 146 | 85 |
| Withdrew: Adverse event | 14 | 5 |
| Withdrew: Death | 39 | 25 |
| Withdrew: Lost to follow-up | 31 | 23 |
| Withdrew: Physician decision | 6 | 0 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 53 | 31 |
| Withdrew: The subject was randomized, but did not take any investigational product | 1 | 0 |
The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.
| percentage of glycated hemoglobin | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Change in HbA1c From Baseline to Week 24 | -0.85 (-0.90 to -0.80) | -0.37 (-0.44 to -0.30) |
To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes
| Percentage of HbA1c | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin | -0.84 (-0.92 to -0.77) | -0.32 (-0.43 to -0.22) |
To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo
| kg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Change in Body Weight From Baseline to Week 48 | -3.03 (-3.27 to -2.80) | -0.38 (-0.72 to -0.04) |
To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline | -9.83 (-11.28 to -8.38) | -6.87 (-8.95 to -4.78) |
To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks
| Percentage of HbA1c | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Week 6 | -0.69 (-0.72 to -0.65) | -0.24 (-0.28 to -0.19) |
| Week 12 | -0.89 (-0.94 to -0.85) | -0.34 (-0.39 to -0.28) |
| Week 24 | -0.84 (-0.89 to -0.79) | -0.37 (-0.45 to -0.30) |
| Week 36 | -0.86 (-0.92 to -0.81) | -0.39 (-0.47 to -0.32) |
| Week 48 | -0.84 (-0.90 to -0.79) | -0.38 (-0.46 to -0.30) |
| Week 72 | -0.76 (-0.83 to -0.70) | -0.34 (-0.44 to -0.25) |
| Week 96 | -0.68 (-0.75 to -0.62) | -0.29 (-0.39 to -0.20) |
| Week 120 | -0.65 (-0.73 to -0.58) | -0.22 (-0.33 to -0.11) |
| Week 144 | -0.62 (-0.71 to -0.53) | -0.23 (-0.37 to -0.10) |
| Week 168 | -0.56 (-0.67 to -0.45) | -0.29 (-0.46 to -0.13) |
To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks
| mmol/L | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Week 6 | -1.28 (-1.40 to -1.16) | 0.07 (-0.10 to 0.24) |
| Week 12 | -1.33 (-1.46 to -1.21) | 0.06 (-0.12 to 0.23) |
| Week 24 | -1.43 (-1.56 to -1.30) | -0.05 (-0.23 to 0.13) |
| Week 36 | -1.21 (-1.36 to -1.06) | -0.06 (-0.27 to 0.15) |
| Week 48 | -1.36 (-1.50 to -1.21) | -0.12 (-0.33 to 0.08) |
| Week 72 | -1.14 (-1.30 to -0.98) | -0.15 (-0.38 to 0.07) |
| Week 96 | -1.16 (-1.32 to -0.99) | 0.04 (-0.20 to 0.29) |
| Week 120 | -0.90 (-1.09 to -0.71) | 0.25 (-0.02 to 0.53) |
| Week 144 | -1.03 (-1.24 to -0.81) | -0.40 (-0.72 to -0.08) |
| Week 168 | -1.06 (-1.39 to -0.73) | -0.55 (-1.04 to -0.07) |
To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period
| Proportion of participants | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification | 0.06 (0.05 to 0.08) | 0.18 (0.15 to 0.21) |
To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period
| Proportion of participants | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification | 0.06 (0.05 to 0.08) | 0.18 (0.15 to 0.21) |
To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period
| Proportion of participants | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent | 0.09 (0.08 to 0.11) | 0.05 (0.03 to 0.07) |
To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study
| Proportion of participants | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent | 0.09 (0.08 to 0.11) | 0.05 (0.03 to 0.07) |
To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline
| Proportion of participants | All Subjects: Bexagliflozin Tablets, 20 mg | All Subjects: Placebo Tablets | Subjects With HF History: Bexagliflozin Tablets, 20 mg | Subjects With HF History: Placebo |
|---|---|---|---|---|
| Proportion of Participants With Incidence of Hospitalization for Heart Failure | 0.01 (0.01 to 0.02) | 0.02 (0.01 to 0.03) | 0.05 (0.03 to 0.08) | 0.09 (0.05 to 0.15) |
Collected over Adverse event data were collected from the first dose to the last day of follow up (4 weeks after the End of Treatment visit, an average of 127 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bexagliflozin Tablets, 20 mg | 39/1,132 (3.4%) | 373/1,132 (33%) | 739/1,132 (65.3%) |
| Placebo Tablets | 26/567 (4.6%) | 208/567 (36.7%) | 386/567 (68.1%) |
| Event | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Angina unstableCardiac disorders | 31/1132 | 19/567 |
| Acute myocardial infarctionCardiac disorders | 31/1132 | 14/567 |
| Cardiac failure congestiveCardiac disorders | 18/1132 | 15/567 |
| Myocardial infarctionCardiac disorders | 11/1132 | 13/567 |
| Angina pectorisCardiac disorders | 16/1132 | 11/567 |
| Cardiac failureCardiac disorders | 21/1132 | 7/567 |
| Coronary artery diseaseCardiac disorders | 21/1132 | 6/567 |
| PneumoniaInfections and infestations | 11/1132 | 10/567 |
| Atrial fibrillationCardiac disorders | 15/1132 | 9/567 |
| HypoglycaemiaMetabolism and nutrition disorders | 14/1132 | 8/567 |
| Event | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 475/1132 | 246/567 |
| Urinary tract infectionInfections and infestations | 128/1132 | 60/567 |
| Upper respiratory tract infectionInfections and infestations | 112/1132 | 53/567 |
| NasopharyngitisInfections and infestations | 96/1132 | 39/567 |
| HyperglycaemiaMetabolism and nutrition disorders | 68/1132 | 41/567 |
| NauseaGastrointestinal disorders | 54/1132 | 37/567 |
| DiarrhoeaGastrointestinal disorders | 72/1132 | 31/567 |
| HypertensionVascular disorders | 45/1132 | 36/567 |
| BronchitisInfections and infestations | 52/1132 | 34/567 |
| Back painMusculoskeletal and connective tissue disorders | 66/1132 | 33/567 |
| Age, Categorical(Participants) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 562 | 276 | 838 |
| >=65 years | 571 | 291 | 862 |
| Age, Continuous(years) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| Mean | 64.4 ± 7.94 | 64.6 ± 8.01 | 64.4 ± 7.96 |
| Sex: Female, Male(Participants) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| Female | 341 | 177 | 518 |
| Male | 792 | 390 | 1182 |
| Ethnicity (NIH/OMB)(Participants) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| Hispanic or Latino | 166 | 93 | 259 |
| Not Hispanic or Latino | 967 | 474 | 1441 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| American Indian or Alaska Native | 98 | 54 | 152 |
| Asian | 108 | 55 | 163 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 46 | 28 | 74 |
| White | 879 | 430 | 1309 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| Canada | 67 | 24 | 91 |
| Netherlands | 36 | 18 | 54 |
| South Korea | 48 | 26 | 74 |
| United States | 397 | 205 | 602 |
| Czechia | 118 | 52 | 170 |
| Taiwan | 46 | 20 | 66 |
| Denmark | 17 | 10 | 27 |
| Poland | 196 | 97 | 293 |
| Mexico | 121 | 62 | 183 |
| Russia | 87 | 53 | 140 |
| Cardiovascular Risk Groups(Participants) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| Group 1: History of atherosclerotic vascular disease | 703 | 362 | 1065 |
| Group 2: History of heart failure | 166 | 80 | 246 |
| Group 3: Age >= 55 years with > 2 risk factors | 264 | 125 | 389 |
| Body Weight(kg) | Bexagliflozin Tablets, 20 mg | Placebo Tablets | Total |
|---|---|---|---|
| Mean | 94.59 ± 21.87 | 92.62 ± 19.999 | 93.94 ± 20.745 |
14 further baseline measures are reported on the registry.
Showing the first 100 of 157 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2015 to primary completion in Aug 2018, 34 months.
Results were first posted in Jul 2021, 2 years 11 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 34 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bexagliflozin
Theracos